Interstitial foam cells and oxidized lipoprotein in human glomerular disease

Modern Pathology

Volumn 12, Issue 1, 1999, Pages 33-40

  Magil, Alex B ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Apollpoproteins; Foam cells; Interstitium; Macrophage; Oxidized lipoprotein

Indexed keywords

LIPOPROTEIN;

ALPORT SYNDROME; ARTICLE; CELL VACUOLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ELECTRON MICROSCOPY; EXTRACELLULAR MATRIX; FOAM CELL; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL NEPHRITIS; INTERSTITIUM; KIDNEY BIOPSY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PATHOGENESIS; PRIORITY JOURNAL; STAINING;

ADOLESCENT; ADULT; CHILD; FEMALE; FOAM CELLS; HISTOCYTOCHEMISTRY; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES; KIDNEY GLOMERULUS; LIPOPROTEINS, LDL; MALE; MICROSCOPY, ELECTRON;

EID: 0032935607     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low-density lipoproteins from cholesterol-fed animals of several species. Proc Natl Acad Sci U S A 1979;76: 333-7.
2. Fogelman AM, Schecter I, Seager J, Hokom M, Child JS, Edwards PA. Malonaldehyde alteration of low-density lipoprotein leads to cholesteryl ester accumulation in human monocytes-macrophages. Proc Natl Acad Sci U S A 1980;77: 2214-8.
3. Parthasarathy SD, Printz J, Boyd D, Joy L, Steinberg D. Macrophage oxidation of low-density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis 1986;6:505-10.
4. Vijayagopal P, Srinivasan SR, Xu J-H, Dalferes ER Jr, Radhakrishnamurthy B, Berenson GS. Lipoprotein-proteoglycan complexes induce continued cholesteryl ester accumulation in foam cells from rabbit atherosclerotic lesions. J Clin Invest 1993;91:1011-8.
5. Khoo JC, Miller E, McLaughlin P, Steinberg D. Enhanced macrophage uptake of low-density lipoprotein after self-aggregation. Arteriosclerosis 1988;8:348-58.
6. Curtiss LK, Black AS, Takagi Y, Plow EF. New mechanism for foam cell generation in atherosclerotic lesions. J Clin Invest 1987;80:367-73.
7. Curtiss LK, Dyer CA, Banka CL, Black AS. Platelet-mediated foam cell formation in atherosclerosis. Clin Invest Med 1990; 13:189-95.
8. Ishihara T, Akizuki S, Yokota T, Takahashi M, Uchino F, Matsumoto N. Foamy cells associated with platelet phagocytosis. Am J Pathol 1984;114:104-11.
9. Ishihara T, Matsumoto M, Okuzono Y, Yamashita Y, Nagasawa T, Kawano H, et al. Foamy cell syndrome associated with repeated platelet transfusions. Acta Pathol Jpn 1986;36: 1863-9.
10. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest 1988;58:249-61.
11. Witztum JL, Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-92.
12. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995;91:2488-96.
13. Magil AB, Frohlich JJ, Innis SM, Steinbrecher UP. Oxidized low-density lipoprotein in experimental focal glomerulosclerosis. Kidney Int 1993;43:1243-50.
14. Eddy AA. Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. Kidney Int 1996;50: 1139-49.
15. Nolasco F, Cameron JS, Reuben R, Hartley B, Carvalho F, Coelho RA. Interstitial foam cells in the nephrotic syndrome belong to the monocyte lineage. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1984;21:666-71.
16. Schonholzer KW, Waldron M, Magil AB. Intraglomerular foam cells and human focal glomerulosclerosis. Nephron 1992;62:130-6.
17. Poucell S, Thorner P, Balfe JW, Baumal R. Interstitial foam cells in renal biopsies: an aid in differentiating idiopathic membranoproliferative glomerulonephritis (type I) and membranoproliferative glomerulonephritis associated with systemic lupus erythematosus. Child Nephrol Urol 1989;9:106-11.
18. Franco M, Schmitt F, Rejaili WA, Viero RM, Bacchi CE. Interstitial foam cells are macrophages. Histopathology 1992; 20:173-6.
19. Magil AB, Cohen AH. Monocytes and focal glomerulosclerosis. Lab Invest 1989;61:404-9.
20. Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 1988;33: 917-24.
21. Magil AB. Focal and segmental glomerulosclerosis. Mod Pathol 1991;4:383-91.
22. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50.
23. Tisher CC, Brenner BM, editors. Renal pathology with clinical and functional correlations. 2nd ed. Philadelphia: Lippincott; 1994.
24. Zhang H, Yang Y, Steinbrecher UP. Structural requirements for the binding of modified proteins to the scavenger receptor of macrophages. J Biol Chem 1993;268:5535-42.
25. Marcel YL, Provost PR, Koa H, Raffai E, Dac NV, Fruchart JC, et al. The epitopes of apolipoprotein A-I define structural domains including a mobile middle region. J Biol Chem 1991;266:3644-53.
26. Milne RW, Douste-Blazy P, Marcel YL, Retegui L. Characterization of monoclonal antibodies against human apolipoprotein E. J Clin Invest 1981;68:111-7.
27. Rosen S, Pirani CL, Muehrcke RC. Renal interstitial foam cells: a light and electron microscopic study. Am J Clin Pathol 1966;45:32-41.
28. Weiss LM, Arber DA, Chang KL. CD68: a review. Appl Immunohistochem 1994;2:2-8.
29. Vora DK, Fang ZT, Parhami F, Fogelman AM, Territo MC, Berliner JA. P-selectin induction by MM-LDL and its expression in human atherosclerotic lesions [abstract]. Circulation 1994;90:I83.
30. Lehr HA, Hubner D, Nolte B, Finckh B, Beiegel U, Kohlschutter A, et al. Oxidatively modified human LDL stimulates leukocyte adherence to the microvascular endothelium in vivo. Res Exp Med (Berl) 1991;191:85-90.
31. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low-density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A 1987;84:2995-8.
32. Quinn MT, Parthasarathy S, Steinberg D. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein. Proc Natl Acad Sci U S A 1985;82:5949-53.
33. Cushing SD, Berliner JA Valente AJ, Territo MC, Navab M, Parhami F, et al. Minimally modified low-density lipoprotein induces monocyte chemotactic protein-1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 1991;87:5134-8.
34. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, et al. Induction of endothelial expression of granulocyte- and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990;344:254-7.
35. Schwartz D, Chaverri-Almada L, Berliner JA, Kirchgessenr T, Quismorio DC, Fang ZT, et al. The role of a gro homologue in monocyte adhesion to endothelium. J Clin Invest 1994;94: 1968-73.
36. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, et al. Minimally modified low-density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990;85:1260-6.
37. Frostegard J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 1991;90:119-26.
38. Hessler JR, Robertson AL Jr, Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979;32:213-29.
39. Morel DW, Di Carleto PE, Chisolm GM. Endothelial and smooth muscle cells alter low-density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 1984;4:357-64.
40. Nathan CF. Secretory products of macrophages. J Clin Invest 1987;79:319-26.
41. Furie MB, Randolph GJ. Chemokines and tissue injury. Am J Pathol 1995;146:1287-301.
42. Abboud HE. Growth factors in glomerulonephritis. Kidney Int 1993;43:252-67.
43. Eddy AA. Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 1994;5:1273-87.
44. Miller K, Dresner IG, Michael AF. Localization of platelet antigens in human kidney disease. Kidney Int 1980;18:472-9.
45. Parbtani A, Frampton G, Cameron JS. Platelet and plasma serotonin concentrations in glomerulonephritis, II. Clin Nephrol 1980;14:112-23.
46. Duffus P, Parbtani A, Frampton G, Cameron JS. Intraglomerular localization of platelet related antigens, platelet factor 4 and β-thromboglobulin in glomerulonephritis. Clin Nephrol 1982;17:288-97.
47. Shore VG, Forte T, Licht H, Lewis SB. Serum and urinary lipoproteins in human nephrotic syndrome: evidence for renal catabolism of lipoproteins. Metabolism 1982;31:258-68.
48. Moorhead JF, El-Nahas M, Harry D, Persaud JW, Mayne K, Chan MK, et al. Focal glomerular sclerosis and nephrotic syndrome with partial lecithin cholesterol acyltransferase deficiency and discoidal high density lipoprotein in plasma and urine. Lancet 1983;1:936-7.
49. Ong ACM, Moorhead JF. Tubular lipidosis: epiphenomenon or pathogenetic lesion in human renal disease? Kidney Int 1994;45:753-62.
50. Cooper MA, Buddington B, Miller NL, Alfrey AC. Urinary iron speciation in nephrotic syndrome. Am J Kidney Dis 1995;25: 314-9.
51. Malle E, Woenckhaus C, Waeg G, Esterbauer H, Grone EF, Grone H-J. Immunological evidence for hypochlorite-modified proteins in human kidney. Am J Pathol 1997;150: 603-15.
52. Weiss SJ, LoBuglio AF. Phagocyte-generated oxygen metabolites and cellular injury. Lab Invest 1982;47:5-18.
53. Hazell LJ, Stocker R. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J 1993; 290:165-72.
54. O'Brien KD, Alpers CE, Hokanson JE, Wang S, Chait A. Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. Circulation 1996;94:1216-25.
55. Cameron JS. Tubular and interstitial factors in the progression of glomerulonephritis. Pediatr Nephrol 1992;6:292-303.
56. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20:1-17.
57. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997;51:2-15.
58. Moorhead JF, El-Nahas M, Chan MK, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 1982;ii:1309-11.